Notably, mir-133a was proposed as an important therapeutic target for the treatment of obesity because its overexpression has been found to decrease the expression of genes associated with general adipogenesis (Pparg, Fabp4, Cebpb, and Adipoq), beige adipogenic markers(Tnfrsf9 and Tmem26), and brown adipogenic markers (Prdm16, Pgc1a, Ucp1, Cidea, and miR-196a). The gene discussed is FABP4; the disease is obesity due to melanocortin 4 receptor deficiency.